Abstract
Background/Aims:
This study evaluated the relationship between thyroid nodules and metabolic syndrome (MS) and its components in apparently healthy Koreans.
Methods:
We reviewed the records of 3,298 subjects with no noticeable symptoms who underwent thyroid ultrasound imaging as part of a routine check-up between July 2009 and June 2010; of these, 1,308 were excluded based upon predefined criteria. Among the remaining 1,990 patients, we examined the association between MS and its components and the incidence of thyroid nodules.
Results:
Of the 1,990 subjects included in this study, 38.4% (n = 764) had thyroid nodules and 12.7% (n = 253) had MS. Female sex, older age, higher body mass index, larger waist circumference, higher glycated hemoglobin level, lower thyroid stimulating hormone level, and presence of MS were all closely related with the presence of thyroid nodules (all p < 0.05). Furthermore, the relevant number of MS components showed a positive linear correlation with the occurrence of thyroid nodules (p < 0.001). Evidence of MS alone was not independently associated with thyroid nodules after adjusting for sex and age in a multivariate binary logistic regression analysis; however, glycated hemoglobin for females and waist circumference for males, as well as both age and thyroid stimulating hormone for all patients, were identified as independent predictors for the existence of thyroid nodules (all p < 0.05).
Conclusions:
This study suggests a positive relationship between the components of MS and thyroid nodules in an ostensibly healthy Korean population. Our data support the idea that the recent increase in thyroid nodules is partly due to increases in both MS and obesity.
Keywords: Thyroid nodule, Metabolic syndrome, Obesity
INTRODUCTION
The incidence of thyroid nodules and subsequent thyroid cancer has increased steadily over the last 30 years. Some of this increase may be due to advances in diagnostic tools, including high-resolution ultrasonography and computed tomography, allowing for greater detection of thyroid nodules, which may not have been detected before [1]; however, important changes in the intrinsic characteristics of the general population are also assumed to be involved [2].
Metabolic syndrome (MS) is characterized by a cluster of metabolic risk factors, including central obesity, hypertension, hyperglycemia, and dyslipidemia [3]. As modern industrialization has brought a nutritional surplus and sedentary lifestyles to the general population, the prevalence of MS has been rising exponentially worldwide. Recent data have demonstrated that MS is a risk factor not only for cardiovascular disease and diabetes [4]but also for tumors, including breast, colorectal, pancreatic, and prostate cancers [5-8].
Several previous studies have demonstrated positive associations between MS and thyroid nodules, both benign and malignant, in the general population in Western countries [9,10]. However, it is not known whether a similar association exists among Asian populations. Here, we designed a cross-sectional study to evaluate the relationship between thyroid nodules and MS and its components in ostensibly healthy Koreans.
METHODS
Study subjects
We retrospectively reviewed the records of all participants older than 18 years who underwent thyroid ultrasound exams as part of a routine medical check-up at the Health Promotion Center of Seoul St. Mary's Hospital, a major tertiary hospital in Seoul, Korea, from July 2009 to June 2010. Among the 3,298 asymptomatic subjects identified in our initial screen, we excluded subjects who had missing data in questionnaires; had a different racial or ethnic background; had a self-reported history of diabetes, cardiovascular, or thyroid disease; took lipid-lowering agents such as statins or omega-3 fatty acids; or showed abnormalities on thyroid function tests. Ethical approval for the study protocol and data analysis was obtained from the Institutional Review Board of Seoul St. Mary’s Hospital.
Measurement of anthropometric and biochemical parameters
Height and weight were measured without shoes and while wearing light indoor clothes by trained healthcare personnel. Body mass index was calculated as weight divided by height squared (kg/m2). Systolic and diastolic blood pressure readings were taken in a sitting position with an automatic device after a 10-minute rest. Waist circumference (WC) was measured at the level above the iliac crest, as defined by National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATPIII) guidelines [11].
Blood was drawn after an overnight fast. Fasting plasma glucose (FPG) levels were measured in serum with a modified glucose oxidase/peroxidase method (Sekisui Medical, Tokyo, Japan). Glycated hemoglobin (HbA1c) levels were measured with a G7 glycohemoglobin analyzer (Tosoh Bioscience, Tokyo, Japan). Total cholesterol (TC), triglycerides (TGs), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were determined using standard enzymatic methods (Sekisui Medical). Thyroid stimulating hormone (TSH) and free thyroxine were measured with an electrochemiluminescence immunoassay (Elecsys 1010, Roche, Indianapolis, IN, USA).
MS was defined as the condition in which three or more of the following metabolic components were satisfied, according to NCEP-ATPIII guidelines: (1) WC ≥ 90 cm in males, ≥ 80 cm in females; (2) TG ≥ 150 mg/dL; (3) HDL-C < 40 mg/dL in males, < 50 mg/dL in females; (4) blood pressure ≥ 130/85 mmHg or taking antihypertensive medication; and (5) FPG ≥ 100 mg/dL.
Thyroid evaluation
Thyroid ultrasonography was performed by radiologists using an HDI 5000 (Phillips Ultrasound, Bothell, WA, USA) with a 7-15 MHz transducer, according to the standard protocol of the health promotion center. The diagnosis of thyroid nodules was obtained from a review of radiological reports. A thyroid nodule was defined as discrete lesions distinct from the surrounding thyroid parenchyma, and which had a solid portion regardless of the presence of a cystic portion. The maximal diameter of a thyroid nodule was measured in three planes: longitudinal, transverse, and anteroposterior.
Statistical analysis
Categorical data are expressed as numbers and percentages of subjects. Continuous variables are expressed as the mean ± standard deviation. To evaluate differences in metabolic parameters between those with and without thyroid nodules, categorical variables were analyzed based on the chi-square test and continuous variables were compared with the unpaired t test. To find any association between metabolic components and the prevalence of thyroid nodules, we analyzed the data using a binary logistic regression analysis. A multivariate binary logistic regression analysis was used to determine independent factors for predicting the occurrence of thyroid nodules. A p < 0.05 was considered statistically significant. All analyses were performed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Clinical characteristics of the study subjects
A total of 3,298 subjects were identified who underwent thyroid ultrasound exams as part of a general health check-up. Subjects were excluded from analysis based upon: (1) missing data in patient questionnaires (n = 156); (2) unknown race or ethnicity (n = 63); (3) known thyroid disease (n = 180); (4) use of lipid-lowering agents, including statins or omega-3 fatty acids (n = 279); (5) history of diabetes (n = 175) or cardiovascular disease (n = 123); or (6) thyroid dysfunction (n = 332) (Fig. 1). Based upon these criteria, we were able to identify 1,990 subjects for inclusion in the final study population.
Figure 1.
Selection of study participants.
Metabolic variables and thyroid nodules
The baseline characteristics of the study subjects are summarized in Tables 1 and 2. Among the 1,990 subjects in the final analysis, 764 (38.4%) had thyroid nodules and 253 (12.7%) had MS. The study population consisted of 1,299 females (65.3%) and had a mean age of 49.8 ± 10.0 years.
Table 1.
Metabolic variables and presence of thyroid nodules in subjects with and without thyroid nodules
| Variable | Total (n = 1,990) | With thyroid nodule (n = 764) | Without thyroid nodule (n = 1,226) | p valuea |
|---|---|---|---|---|
| Male sex | 691 (34.7) | 223 (29.2) | 468 (38.2) | < 0.001 |
| Age, yr | 49.8 ± 10.0 | 52.4 ± 9.5 | 48.2 ± 10.0 | < 0.001 |
| Systolic blood pressure, mmHg | 118.4 ± 14.3 | 119.2± 14.3 | 118.0 ± 14.3 | 0.073 |
| Diastolic blood pressure, mmHg | 69.2 ± 10.1 | 69.5± 10.2 | 69.0 ± 10.1 | 0.279 |
| Body mass index, kg/m2 | 22.9 ± 3.1 | 23.2 ± 3.0 | 22.7 ± 3.1 | 0.001 |
| Waist circumference, cm | 82.3 ± 8.1 | 83.2± 8.1 | 81.8 ± 8.1 | < 0.001 |
| Fasting plasma glucose, mg/dL | 87.0 ± 15.2 | 87.7 ± 16.3 | 86.5 ± 14.5 | 0.083 |
| Glycated hemoglobin, % | 5.5 ± 0.5 | 5.6 ± 0.6 | 5.5 ± 0.5 | < 0.001 |
| Total cholesterol, mg/dL | 199.2 ± 34.1 | 199.6 ± 33.9 | 198.9 ± 34.3 | 0.644 |
| Triglyceride, mg/dL | 93.7 ± 66.2 | 94.6 ± 59.0 | 93.1 ± 70.3 | 0.619 |
| HDL-C, mg/dL | 55.2 ± 13.1 | 54.8 ± 12.6 | 55.5 ± 13.4 | 0.253 |
| LDL-C, mg/dL | 120.0 ± 31.1 | 120.3 ± 31.1 | 119.8 ± 31.1 | 0.757 |
| TSH, mIU/L | 2.1 ± 1.1 | 2.0 ± 1.0 | 2.2 ± 1.1 | < 0.001 |
| Free thyroxine, ng/dL | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.2 | 0.883 |
| Metabolic syndrome | 253 (12.7) | 115 (15.1) | 138 (11.3) | 0.015 |
Values are presented as number (%) or mean ± SD.
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TSH, thyroid stimulating hormone.
With thyroid nodule vs. without thyroid nodule.
Table 2.
Metabolic variables and presence of thyroid nodules in subjects with and without metabolic syndrome
| Variable | Total (n = 1,990) | With metabolic syndrome (n = 253) | Without metabolic syndrome (n = 1,737) | p valuea |
|---|---|---|---|---|
| Male sex | 691 (34.7) | 109 (43.1) | 582 (33.5) | 0.004 |
| Age, yr | 49.8 ± 10.0 | 54.9 ± 9.0 | 49.1 ± 9.9 | 0.058 |
| Systolic blood pressure, mmHg | 118.4 ± 14.3 | 129.8 ± 15.5 | 116.8 ± 13.3 | < 0.001 |
| Diastolic blood pressure, mmHg | 69.2 ± 10.1 | 76.3 ± 10.2 | 68.1 ± 9.7 | < 0.001 |
| Body mass index, kg/m2 | 22.9 ± 3.1 | 25.8 ± 2.8 | 22.5 ± 2.9 | < 0.001 |
| Waist circumference, cm | 82.3 ± 8.1 | 90.3 ± 6.9 | 81.2 ± 7.6 | < 0.001 |
| Fasting plasma glucose, mg/dL | 87.0 ± 15.2 | 98.9 ± 26.2 | 85.2 ± 11.8 | < 0.001 |
| Glycated hemoglobin, % | 5.5 ± 0.5 | 6.0 ± 0.9 | 5.5 ± 0.4 | < 0.001 |
| Total cholesterol, mg/dL | 199.2 ± 34.1 | 208.3 ± 39.5 | 197.8 ± 33.1 | < 0.001 |
| Triglyceride, mg/dL | 93.7 ± 66.2 | 173.8 ± 102.4 | 82.1 ± 49.3 | < 0.001 |
| HDL-C, mg/dL | 55.2 ± 13.1 | 42.8 ± 8.8 | 57.0 ± 12.6 | < 0.001 |
| LDL-C, mg/dL | 120.0 ± 31.1 | 128.3 ± 36.0 | 118.8 ± 30.1 | < 0.001 |
| TSH, mIU/L | 2.1 ± 1.1 | 2.2 ± 1.1 | 2.1 ± 1.1 | 0.497 |
| Free thyroxine, ng/dL | 1.3 ± 0.2 | 1.3 ± 0.2 | 1.3 ± 0.2 | 0.592 |
| Thyroid nodule | 764 (38.4) | 115 (45.5) | 649 (37.4) | 0.015 |
| Thyroid nodule size ≥ 1 cm | 186/764 (24.3) | 38/115 (33.0) | 148/649 (22.8) | 0.002 |
| Thyroid nodule multiplicity | 297/764 (38.9) | 49/115 (42.6) | 248/649 (38.2) | 0.346 |
Values are presented as number (%) or mean ± SD.
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TSH, thyroid stimulating hormone.
With metabolic syndrome vs. without metabolic syndrome.
Subjects with thyroid nodules showed a higher female to male ratio (70.8% vs. 61.8%, p < 0.001) and older age (52.4 ± 9.5 years vs. 48.2 ± 10.0 years, p < 0.001) relative to those without thyroid nodules. The prevalence of MS was also higher in subjects with thyroid nodules than in those without (115/764 [15.1%] vs. 138/1,226 [11.3%], p = 0.015). Body mass index, WC, and HbA1c were significantly higher in subjects with thyroid nodules, while blood pressure, FPG, and lipid profiles, including TC, TG, HDL-C, and LDL-C, showed no statistically significant difference between groups. Subjects with MS had a higher prevalence of not only thyroid nodules but also nodules larger than 1 cm (Table 2). However, the prevalence of multiple thyroid nodules did not differ between subjects with or without MS.
Subjects with MS showed a lower female to male ratio (56.9% vs. 66.5%, p = 0.004) and a higher prevalence of thyroid nodules (45.5% vs. 37.4%, p = 0.015) than those without MS. The mean age of the subjects with MS was higher, though this difference was not statistically significant (54.9 ± 9.0 years vs. 49.1 ± 9.9 years, p = 0.058).
As the number of MS components satisfied increased, the proportion of patients with thyroid nodules rose, indicating a strong correlation between MS and thyroid nodules (β = 1.235, p < 0.001) (Fig. 2). However, individual components of MS did not show independent relationships with thyroid nodules after adjusting for sex and age. Moreover, age stratification showed that the prevalence of both thyroid nodules and MS was closely associated with age (Supplementary Fig. 1). To address these apparent discrepancies, we ran a multivariate binary logistic regression analysis to identify clinical variables that could independently predict the existence of thyroid nodules (Table 3). HbA1c levels were a significant predictor of thyroid nodules in females (p = 0.011), while WC was a significant predictor only in males (p = 0.005); higher age and lower TSH were significant factors for predicting thyroid nodules in both sexes (p < 0.001).
Figure 2.
Association between the number of relevant components of metabolic syndrome (MS) and prevalence of thyroid nodules.
Table 3.
Multivariate binary logistic regression analysis of independent predictors for the presence of thyroid nodules (n = 1,635)
| Variable | Odds ratio | p value |
|---|---|---|
| Female sex (n = 1,140) | ||
| Age, yr | 1.059 | < 0.001 |
| Systolic blood pressure, mmHg | 0.989 | 0.151 |
| Diastolic blood pressure, mmHg | 1.005 | 0.635 |
| Waist circumference, cm | 1.011 | 0.283 |
| Glycated hemoglobin, % | 1.512 | 0.011 |
| Triglyceride, mg/dL | 0.999 | 0.245 |
| HDL-C, mg/dL | 0.995 | 0.360 |
| TSH, mIU/L | 0.828 | 0.001 |
| Male sex (n = 595) | ||
| Age, yr | 1.042 | < 0.001 |
| Systolic blood pressure, mmHg | 0.989 | 0.352 |
| Diastolic blood pressure, mmHg | 1.005 | 0.741 |
| Waist circumference, cm | 1.042 | 0.005 |
| Glycated hemoglobin, % | 0.951 | 0.734 |
| Triglyceride, mg/dL | 1.000 | 0.780 |
| HDL-C, mg/dL | 0.999 | 0.882 |
| TSH, mIU/L | 0.714 | < 0.001 |
HDL-C, high density lipoprotein cholesterol; TSH, thyroid stimulating hormone.
DISCUSSION
In this study, we explored the relationship between the presence of thyroid nodules and the components of MS in ostensibly healthy Koreans with no evidence of iodine insufficiency [12]. Our results suggest an association between thyroid nodules and MS components even in healthy populations, which may have important implications for the diagnosis and treatment of thyroid-related diseases.
MS is closely associated with an increase in overall mortality, due not only to increases in cardiovascular complications [4], but also malignant diseases [5-8]. Insulin resistance, a characteristic manifestation of MS, increases glucose and insulin levels, which stimulate cell proliferation. Large population studies revealed that patients with glucose metabolism disorders have a higher chance of both malignancy and mortality [5,13-16]. The tumorigenic effects of MS appear to be mediated through changes in cytokine levels, resulting in decreased expression of tumor suppression genes, and increases in oncogene expression due to inflammation and reactive oxygen species generation; other factors, such as the stimulation of angiogenesis and invasion of malignant cells into normal tissues, may also play a role [5]. While many of the mechanisms underlying these effects remain poorly understood, these activities are well supported by a variety of observational and laboratory studies.
Recent studies suggest that components of MS are possible risk factors for thyroid nodules, beyond many of the well-established ones, including sex, goiter, family history of thyroid cancer, and radiation exposure. MS is thought to trigger thyroid nodules via the stimulation of thyroid proliferation and angiogenesis brought on by hyperinsulinemia, hyperglycemia, and dyslipidemia [17-19]. Our data demonstrate that people with MS had a higher prevalence of thyroid nodules. The subjects with MS also had a higher prevalence of thyroid nodules larger than 1 cm, consistent with a previous study showing a positive association between insulin resistance and thyroid nodule size [19]. Furthermore, we showed that the number of accompanying MS factors had a significant positive correlation with the prevalence of thyroid nodules; the more components of MS were observed, the higher the chance of thyroid nodules. The prevalence of thyroid nodules may be affected by sex [20,21]; as older age was also positively correlated with not only the presence of thyroid nodules, but also MS [22], we analyzed the role of sex independently using multivariate logistic regression. After adjusting for age, higher HbA1c in females and larger WC in males were found to be significant factors for the presence of thyroid nodules.
Many previous studies have shown that hyperglycemia has a strong correlation with thyroid cancer in both sexes [23,24]. Our study demonstrates that hyperglycemia, as indicated by HbA1c levels, showed a significant relationship with the presence of thyroid nodules in women. An interesting finding is that HbA1c levels showed a significant association with thyroid nodules both before and after adjustment for related factors, whereas FPG levels did not. The exclusion of all known diabetic patients to target a metabolically normal population might make these two hyperglycemia-related parameters contradictory. Consistent with our study, a previous univariate analysis of an Icelandic cohort showed the relative risk for women with high 90-minute postprandial glucose levels for thyroid cancer was 1.12 [14], indicating that postprandial glucose levels may be associated with thyroid nodules and, potentially, thyroid cancer. Although the effects of postprandial hyperglycemia on tumor formation have been not well evaluated, hyperglycemia, oxidative stress, endothelial dysfunction, and the formation of advanced glycation end products may all potentially be involved in the pathophysiology of tumor formation [5,25,26]. As HbA1c levels are routinely used to screen for the existence of diabetes [27-30], our center was able to measure these levels across all patients; however, we were unable to evaluate insulin resistance outcomes, such as homeostasis model assessment of insulin resistance, as neither insulin nor c-peptide were routinely measured.
Anthropometric measurements showed inconsistent associations with the prevalence of thyroid cancer. Most studies that have evaluated the relationship between body mass index and thyroid cancer have reported a strong association between them [14,31,32]; however, the significance varied with sex. Kitahara et al. [33] demonstrated a slightly stronger association of WC and weight change with thyroid cancer risk in men versus women, which may be due to a difference in hormone profiles, such as leptin and estrogen, and the metabolic consequences of excess body fat in men and women.
TSH levels were inversely related with thyroid nodules, even though both TSH levels were within normal ranges. One possible explanation is that multiple thyroid nodules could maintain TSH levels at a lower normal range by autonomous hyperfunctioning. TSH has been shown to be suppressed in patients with a multinodular goiter [34], while TSH levels < 2.5 mIU/L may be related to an increased risk of MS [35]. These associations were not replicated in our study, with MS patients showing no increases in TSH levels (Table 2). This difference may be an artifact of the study design, as our study population consisted entirely of patients who underwent thyroid ultrasound imaging.
Our study has several unique clinical features. The most important aspect of this study is its use of clinically healthy subjects. Because we initially excluded all subjects with a history of diabetes or cardiovascular disease and those taking lipid-lowering agents, the prevalence of MS (12.7%) in our study population was much lower than that in the general Korean population, with MS prevalence rates estimated at 31.3% [36]. Although the strict inclusion criteria may have underestimated the effects of abnormal glucose and lipid metabolism on the thyroid, MS components showed significant connections with thyroid nodules. Second, this analysis was based on reliable parameters measured by specialists using standardized methods at a single center. The large number of subjects enrolled is also an important strength of this study.
Despite its many strengths, this study is not without limitations. First, it was a retrospective, cross-sectional study. Therefore, the study population might be biased, as the study population consisted of people who determined by themselves whether they should undergo thyroid ultrasonography. This aspect of the study design may explain why the prevalence of thyroid nodules was similar between sexes, unlike a previous study [21]. A longitudinal cohort study with a more representative population will be needed to address these potential issues. Second, we could not evaluate the association between insulin resistance and thyroid nodules because insulin and C-peptide levels were not available. A lack of cytological or histological results for each nodule is an important limitation. Future studies focusing on more biopsy-proven reports and with a longer follow-up duration will be necessary to provide a more complete and accurate evaluation of the relationship.
This study suggests an association between the components of MS and thyroid nodules in a healthy Korean population. Our data show that female sex, older age, lower TSH, and higher number of accompanying MS components were all positively associated with the presence of thyroid nodules. Future studies evaluating the effects of active interventions, including lifestyle modification and medication adjustments, on components of MS with regard to the incidence of thyroid nodules and, ultimately, the prevention of thyroid cancer, are therefore warranted.
KEY MESSAGE
1. There is a positive relationship between the components of metabolic syndrome (MS) and thyroid nodules in an ostensibly healthy Korean population.
2. A recent increase in thyroid nodules is partly due to increases in both MS and obesity.
Footnotes
No potential conflict of interest relevant to this article was reported.
Supplementary Material
Association between age and the prevalence of metabolic syndrome (MS) and thyroid nodules.
REFERENCES
- 1.Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164–2167. doi: 10.1001/jama.295.18.2164. [DOI] [PubMed] [Google Scholar]
- 2.Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009;18:784–791. doi: 10.1158/1055-9965.EPI-08-0960. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–1428. doi: 10.1016/S0140-6736(05)66378-7. [DOI] [PubMed] [Google Scholar]
- 4.Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8–13. doi: 10.2337/dc06-1414. [DOI] [PubMed] [Google Scholar]
- 5.Pothiwala P, Jain SK, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7:279–288. doi: 10.1089/met.2008.0065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. Menopause. 2013;20:1301–1309. doi: 10.1097/GME.0b013e31828ce95d. [DOI] [PubMed] [Google Scholar]
- 7.Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44:293–297. doi: 10.1016/j.ejca.2007.11.005. [DOI] [PubMed] [Google Scholar]
- 8.Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006;164:769–774. doi: 10.1093/aje/kwj284. [DOI] [PubMed] [Google Scholar]
- 9.Ayturk S, Gursoy A, Kut A, Anil C, Nar A, Tutuncu NB. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol. 2009;161:599–605. doi: 10.1530/EJE-09-0410. [DOI] [PubMed] [Google Scholar]
- 10.Rezzonico JN, Rezzonico M, Pusiol E, Pitoia F, Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab Syndr Relat Disord. 2009;7:375–380. doi: 10.1089/met.2008.0062. [DOI] [PubMed] [Google Scholar]
- 11.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
- 12.Kim JY, Kim KR. Dietary iodine intake and urinary iodine excretion in patients with thyroid diseases. Yonsei Med J. 2000;41:22–28. doi: 10.3349/ymj.2000.41.1.22. [DOI] [PubMed] [Google Scholar]
- 13.Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol. 2003;157:1092–1100. doi: 10.1093/aje/kwg100. [DOI] [PubMed] [Google Scholar]
- 14.Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: a cohort study on a population of 22,946 Icelanders. Cancer Epidemiol Biomarkers Prev. 1997;6:863–873. [PubMed] [Google Scholar]
- 15.Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579–591. doi: 10.1038/nrc1408. [DOI] [PubMed] [Google Scholar]
- 16.Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res. 2004;14:261–269. doi: 10.1016/j.ghir.2004.01.005. [DOI] [PubMed] [Google Scholar]
- 17.Iribarren C, Haselkorn T, Tekawa IS, Friedman GD. Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer. 2001;93:745–750. doi: 10.1002/ijc.1377. [DOI] [PubMed] [Google Scholar]
- 18.Yin J, Wang C, Shao Q, et al. Relationship between the prevalence of thyroid nodules and metabolic syndrome in the iodine-adequate area of Hangzhou, China: a cross-sectional and cohort study. Int J Endocrinol. 2014;2014:675796. doi: 10.1155/2014/675796. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wang K, Yang Y, Wu Y, et al. The association between insulin resistance and vascularization of thyroid nodules. J Clin Endocrinol Metab. 2015;100:184–192. doi: 10.1210/jc.2014-2723. [DOI] [PubMed] [Google Scholar]
- 20.Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553–559. doi: 10.1056/NEJM199302253280807. [DOI] [PubMed] [Google Scholar]
- 21.Kim JY, Jung EJ, Park ST, et al. Body size and thyroid nodules in healthy Korean population. J Korean Surg Soc. 2012;82:13–17. doi: 10.4174/jkss.2012.82.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study. BMC Public Health. 2007;7:220. doi: 10.1186/1471-2458-7-220. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Zhan YS, Feng L, Tang SH, et al. Glucose metabolism disorders in cancer patients in a Chinese population. Med Oncol. 2010;27:177–184. doi: 10.1007/s12032-009-9189-9. [DOI] [PubMed] [Google Scholar]
- 24.Zivaljevic V, Vlajinac H, Jankovic R, Marinkovic J, Diklic A, Paunovic I. Case-control study of anaplastic thyroid cancer. Tumori. 2004;90:9–12. doi: 10.1177/030089160409000103. [DOI] [PubMed] [Google Scholar]
- 25.Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med. 2003;163:1306–1316. doi: 10.1001/archinte.163.11.1306. [DOI] [PubMed] [Google Scholar]
- 26.Heine RJ, Balkau B, Ceriello A, Del Prato S, Horton ES, Taskinen MR. What does postprandial hyperglycaemia mean? Diabet Med. 2004;21:208–213. doi: 10.1111/j.1464-5491.2004.01149.x. [DOI] [PubMed] [Google Scholar]
- 27.Ko SH, Kim SR, Kim DJ, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J. 2011;35:431–436. doi: 10.4093/dmj.2011.35.5.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–1334. doi: 10.2337/dc09-9033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab. 2008;93:2447–2453. doi: 10.1210/jc.2007-2174. [DOI] [PubMed] [Google Scholar]
- 30.Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med. 2007;24:333–343. doi: 10.1111/j.1464-5491.2007.02106.x. [DOI] [PubMed] [Google Scholar]
- 31.Dal Maso L, La Vecchia C, Franceschi S, et al. A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control. 2000;11:137–144. doi: 10.1023/a:1008938520101. [DOI] [PubMed] [Google Scholar]
- 32.Engeland A, Tretli S, Akslen LA, Bjorge T. Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer. 2006;95:366–370. doi: 10.1038/sj.bjc.6603249. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kitahara CM, Platz EA, Park Y, Hollenbeck AR, Schatzkin A, Berrington de Gonzalez A. Body fat distribution, weight change during adulthood, and thyroid cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer. 2012;130:1411–1419. doi: 10.1002/ijc.26161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Elte JW, Bussemaker JK, Haak A. The natural history of euthyroid multinodular goitre. Postgrad Med J. 1990;66:186–190. doi: 10.1136/pgmj.66.773.186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Oh JY, Sung YA, Lee HJ. Elevated thyroid stimulating hormone levels are associated with metabolic syndrome in euthyroid young women. Korean J Intern Med. 2013;28:180–186. doi: 10.3904/kjim.2013.28.2.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Lim S, Shin H, Song JH, et al. Increasing prevalence of metabolic syndrome in Korea: the Korean National Health and Nutrition Examination Survey for 1998-2007. Diabetes Care. 2011;34:1323–1328. doi: 10.2337/dc10-2109. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Association between age and the prevalence of metabolic syndrome (MS) and thyroid nodules.